A Study on Weight Loss Cause as per the Side Effect of Liraglutide.
Cardiovasc Ther · 2022
Last updated 2026-05-28In a study of 157 patients, only 40.8% stayed on liraglutide for 6 months. At 3 months, weight loss ranged from 3.4% to 7.9% across groups, but by 6 months, weight loss slowed to between 1.7% and 2.2%. Side effects did not significantly impact the amount of weight lost.
AI summary of the abstract below.
| Journal | Cardiovasc Ther, 2022 |
|---|---|
| Citations | 4 |
| Relative citation ratio | 0.35 |
| NIH percentile | 21 |
| Molecules | liraglutide |
| Conditions studied | Obesity |
Abstract
PURPOSE: Liraglutide is known to have much lower weight loss effects in real clinical fields than in randomized clinical trials because of its side effects (SE) and discomfort associated with injections. This study is aimed at determining whether the side effects of liraglutide affect weight reduction and its maintenance in real-world practice.
METHODS: Endocrinologists conducted a retrospective chart review of data from two tertiary university hospitals. All patients who had been prescribed liraglutide at least once between January 2014 and December 2019 were included. For an average of 3 and 6 months, weight changes due to the presence or absence of SE and discontinuation (MAIN or STOP) of liraglutide were checked.
RESULTS: Only 40.8% (64/157) of the patients remained on liraglutide for 6 months; 14.7% (23/157) maintained the drug despite SEs (MAIN_SE(+)), and 40.1% (63/157) discontinued the drug despite not having SEs (STOP_SE(-)). At 3 months, there was -5.9 ± 0.6%, -7.9 ± 0.9%, -4.5 ± 0.5%, and -3.4 ± 0.6% weight reduction in the MAIN_SE(-), MAIN_SE(+), STOP_SE(-), and STOP_SE(+) groups, respectively (all < 0.001 compared to the baseline). However, there were no significant differences in the weight loss between the MAIN ( = 0.062) and STOP ( = 0.204) groups. At 6 months, the weight reduction was -2.0 ± 0.5% ( < 0.001) in MAIN_SE(-), -2.2 ± 0.7% ( < 0.005) in MAIN_SE(+), -1.7 ± 0.7% ( < 0.01) in STOP_SE(-), and -2.0 ± 0.6% ( = 0.01) in STOP_SE(+), compared to baseline. SEs also caused no significant differences in weight loss between the MAIN ( = 0.787) and STOP ( = 0.694) groups.
CONCLUSIONS: Our study confirmed that the side effects of liraglutide did not affect weight reduction. Moreover, in the real world, the continuous rate of liraglutide use is not high, and the weight gradually increases after 3 months. Therefore, in addition to the side effects of liraglutide, the medical staff should consider various factors that affect drug adherence, consider ways to increase compliance, and continue to ensure management so that patients can maintain their weight.
Verbatim abstract via PubMed 36540096 ↗
Related research
- Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.
- A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management.
- Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study.
- Liraglutide and Renal Outcomes in Type 2 Diabetes.
- Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes: The SCALE Diabetes Randomized Clinical Trial.
- The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss.
- Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial.
- The Discovery and Development of Liraglutide and Semaglutide.